Beacon Therapeutics Highlights Series C Financing and Clinical Progress in XLRP Program

According to a recent LinkedIn post from Beacon Therapeutics, CEO Lance Baldo and members of the management team plan to attend TD Cowen’s 46th Annual Health Care Conference in Boston from March 2–4. The post also references a recently closed oversubscribed Series C financing round exceeding $75 million and initial patient dosing in the LANDSCAPE clinical trial of laru-zova for X-linked retinitis pigmentosa (XLRP).

The post suggests Beacon is moving from capital-raising into active clinical execution in ophthalmic gene therapy, which may reduce financing overhang in the near term while increasing clinical and regulatory risk exposure. Participation in a high-profile healthcare conference could facilitate additional investor and partner engagement, potentially supporting future funding, strategic collaborations, and visibility within the rare disease and gene therapy segments.